Denmark’s economy rebounded in the second quarter, as the strength of the broader pharmaceuticals industry helped to outweigh ...

The manufacturer of Ozempic (and other Semaglutide brands) faces over $2 billion in lawsuits filed by over 1,800 patients claiming blindness, stomach paralysis, and more.

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

Viking Therapeutics' stock crashed 40% in early trading on Tuesday after a phase 2 trial of its weight-loss pill showed a ...

Viking Therapeutics stock crashed Tuesday — losing more than a third of its value — on mixed results for its weight-loss pill.

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Viking Therapeutics (NASDAQ: VKTX) suffered a brutal market sell-off on Tuesday, with shares plunging over 40% in one of the ...

Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes, which has raised questions.

Eli Lilly and Novo Nordisk are expected to price their new obesity pills in line with existing injections, as analysts cite ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...